Research on Solvonis Therapeutics Plc (SVNS:LON) from Turner Pope Investments
Solvonis Therapeutics plc has successfully raised £1.3 million through a placing of new ordinary shares at 0.12p per share, with the proceeds intended to advance key clinical and regulatory milestones for its central nervous system disorder therapeutics. The funds will support the assessment of international sites for the SVN-001 Phase 3 study, the advancement of SVN-002 towards an Investigational New Drug submission and Phase 2b readiness in the United States, and the progression of SVN-015 alongside the US National Institute on Drug Abuse. Turner Pope Investments has been appointed as the Company's corporate broker.
View Full ResearchDisclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
